Therefore, our observation indicates that the therapeutic intervention of SphK2/S1P signaling pathway may be effective in the early treatment of emphysema but may not be applicable to the research and treatment of end-stage COPD. The gene discussed is SPHK2; the disease is pulmonary emphysema.